<DOC>
	<DOC>NCT00758225</DOC>
	<brief_summary>The scientific aim of the present extension study is to monitor long-term safety and tolerability of idebenone in patients with DMD. Furthermore, the long-term effect on respiratory, cardiac and motor functions, and skeletal muscle strength/function will be assessed.</brief_summary>
	<brief_title>Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
	<mesh_term>Idebenone</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Completion of study SNTII001 Body weight â‰¥ 25 kg Glucocorticosteroids and ACEinhibitors are allowed, if on stable dosage within 2 months prior to inclusion Eligibility to participate in the present extension study as confirmed by the investigator Safety or tolerability issues arising during the course of SNTII001 which in the opinion of the investigator preclude further treatment with idebenone Clinically significant abnormalities of haematology or biochemistry Abuse of drugs or alcohol Use of coenzyme Q10 or idebenone within 30 days prior to inclusion Intake of any investigational drug within 30 days prior to inclusion Symptomatic heart failure Previous history of ventricular arrhythmias (other than isolated ventricular extrasystole); ventricular arrhythmias presented at baseline Known individual hypersensitivity to idebenone or to any of the excipients</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Duchenne Muscular Dystrophy</keyword>
	<keyword>DMD</keyword>
	<keyword>Duchenne</keyword>
	<keyword>Idebenone</keyword>
</DOC>